Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study

HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MBC) patients treated with high-dose chemotherapy (HDC). HER-2 status is also a predictive factor and when trastuzumab is administered in combination with or sequentially to chemotherapy, a significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Bengala, C, Zamagni, C, Pedrazzoli, P, Matteucci, P, Ballestrero, A, Da Prada, G, Martino, M, Rosti, G, Danova, M, Bregni, M, Jovic, G, Guarneri, V, Maur, M, Conte, P F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361220/
https://www.ncbi.nlm.nih.gov/pubmed/16570045
http://dx.doi.org/10.1038/sj.bjc.6603060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361220/
https://www.ncbi.nlm.nih.gov/pubmed/16570045
http://dx.doi.org/10.1038/sj.bjc.6603060

Ejemplares similares